← Back to SEM filing summaryOriginal filing text · Part I
Item 3 — Quantitative and Qualitative Disclosures About Market Risk
Select Medical Holdings Corp · 10-Q · Q1 FY2026 · Period ended Mar 31, 2026
View complete filing on SEC EDGAR ↗This is the extracted source text from the SEC filing. Formatting may differ from the original document.
We are subject to interest rate risk in connection with our variable rate long-term indebtedness. Our principal interest rate exposure relates to the loans outstanding under our credit facilities, which bear interest rates that are indexed against Term SOFR.
At March 31, 2026, Select had outstanding borrowings under its credit facilities consisting of a $1,036.9 million term loan (excluding unamortized original issue discounts and debt issuance costs of $6.8 million) and $125.0 million of borrowings under its revolving facility, which bear interest at variable rates.
In order to mitigate our exposure to rising interest rates, we entered into an interest rate cap effective on March 31, 2025, which limits the Term SOFR rate to 4.5% on $1.0 billion of principal outstanding under our term loan. The agreement applies to interest payments through March 31, 2028. As of March 31, 2026, the Term SOFR rate was 3.66%. As of March 31, 2026, we had $36.9 million of term loan borrowings which would still be subject to variable interest rates if the Term SOFR rate were to exceed 4.5%.
As of March 31, 2026, the first 0.25% increase in market interest rates will impact the annual interest expense on our variable rate debt by approximately $2.9 million per year.